-
Teva Pharmaceuticals International GmbH et al v. Eli Lilly and Company DC CAFC
- 1:18-cv-12029
- D. Mass.
- Judge: Allison Dale Burroughs
- Filed: 09/27/2018
- Closed: 09/28/2023
- Latest Docket Entry: 01/05/2024
- PACER
- Docket updated daily
2
Plaintiffs
1
Defendant
1
Accused
Product
9
Patents-in-Suit
1,828
Days in
Litigation
-
Teva Pharmaceuticals International GmbH et al v. Eli Lilly and Company DC CAFC
- 1:18-cv-12029
- D. Mass.
- Judge: Allison Dale Burroughs
- Filed: 09/27/2018
- Closed: 09/28/2023
- Latest Docket Entry: 01/05/2024
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 30 |
The method of claim 17, wherein said anti-CGRP antagonist antibody is a humanized monoclonal antibody.
|
Invalid
Entry 695 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 5 |
The method of claim 1, wherein the headache is a migraine with or without aura, hemiplegic migraine, cluster headache, migrainous neuralgia, chronic headache, or tension headache.
|
Invalid
Entry 695 |
| 6 |
The method of claim 1, wherein the headache is a migraine.
|
Invalid
Entry 695 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 5 |
The method of claim 1, wherein the headache is a migraine with or without aura, hemiplegic migraine, cluster headache, migrainous neuralgia, chronic headache, or tension headache.
|
Invalid
Entry 695 |
| 6 |
The method of claim 1, wherein the headache is a migraine.
|
Invalid
Entry 695 |
-
Infringement
Eli Lilly and Company
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Galcanezumab Product | US 8,586,045 B2 |
18, 21, 30
|
Willful infringement
Entry 513Entry 638 Entry 593 |
| Galcanezumab Product | US 9,884,907 B2 |
5, 6
|
Willful infringement
Entry 638Entry 593 |
| Galcanezumab Product | US 9,884,908 B2 |
5, 6
|
Willful infringement
Entry 638Entry 593 |
-
Damages
